Cytokinetics
Developer of muscle-directed medicines led by MYQORZO for hypertrophic cardiomyopathy.
$72.50
After-hours close+0.39 (+0.54%)
At close$72.11(−7.43%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 138.79%Insiders 0.83%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 124.43M · Float 119.24M · 95.8% free float
Institutions13F, as of Jun 30, 2026
511 holders · 172.70M shares · 94 new positions · 335 increased · 104 reduced · 56 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 20.09M | 16.15% | +3.55M | Aug 7, 2026 |
| T. Rowe Price Investment Management, Inc. | 18.72M | 15.04% | +1.19M | Aug 14, 2026 |
| Wellington Management Group LLP | 6.93M | 5.57% | −1.08M | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 6.71M | 5.39% | +868.0K | Aug 13, 2026 |
| State Street Corp | 6.49M | 5.22% | +749.0K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 6.12M | 4.92% | +628.9K | Aug 13, 2026 |
| FMR LLC | 5.03M | 4.04% | −5.69M | Aug 13, 2026 |
| Avoro Capital Advisors LLC | 5.00M | 4.02% | +1.67M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 14.50% | 17.72M | 13G | Feb 17, 2026 ↗ |
| BlackRock, Inc. | 13.00% | 15.25M | Oct 23, 2024 ↗ | |
| FMR LLC | 9.00% | 11.14M | 13G | May 6, 2026 ↗ |
| Vanguard Capital Management | 5.21% | 6.42M | 13G | Apr 29, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Robert I. Blum | director, officer: President & CEO | 377.8K | 0.30% | Aug 10, 2026 |
| Fady Ibraham Malik | officer: EVP Research & Development | 153.9K | 0.12% | Aug 18, 2026 |
| Jeffrey Hessekiel | officer: Chief Legal & Admin Officer | 107.9K | 0.09% | Mar 17, 2026 |
| John T. Henderson | director | 78.4K | 0.06% | Jul 16, 2026 |
| Sung Lee | officer: EVP, Chief Financial Officer | 63.2K | 0.05% | Jul 2, 2026 |
| Andrew Callos | officer: EVP, Chief Commercial Officer | 58.6K | 0.05% | Jul 30, 2026 |
| Wendell Wierenga | director | 35.6K | 0.03% | Jul 16, 2026 |
| Nancy Wysenski | director | 34.0K | 0.03% | Jul 16, 2026 |
| Wendall Wierenga | director | 32.3K | 0.03% | Jul 16, 2025 |
| Muna Bhanji | director | 26.4K | 0.02% | May 27, 2026 |
14 ten-percent owners hold 5.23M shares by Form 4, outside the officers-and-directors figure above · 24 people have not refiled in the last 18 months (1.68M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Fady Ibraham Malikofficer: EVP Research & Development | Sale | 3,500 | $75.82 | 153,902 |
| Aug 10, 2026 | Robert I. Blumdirector, officer: President & CEO | Sale | 7,500 | $76.76 | 377,820 |
| Jul 30, 2026 | Andrew Callosofficer: EVP, Chief Commercial Officer | Sale | 14,000 | $79.88 | 58,555 |
| Jul 27, 2026 | Robert I. Blumdirector, officer: President & CEO | Sale | 7,500 | $80.87 | 377,820 |
| Jul 21, 2026 | Fady Ibraham Malikofficer: EVP Research & Development | Sale | 3,500 | $80.59 | 153,902 |
| Jul 13, 2026 | Robert I. Blumdirector, officer: President & CEO | Sale | 7,490 | $82.02 | 377,820 |
| Jul 7, 2026 | Fady Ibraham Malikofficer: EVP Research & Development | Sale | 3,500 | $86.62 | 153,902 |
| Jul 1, 2026 | Sung Leeofficer: EVP, Chief Financial Officer | Sale | 1,112 | $87.79 | 63,221 |
| Jul 1, 2026 | Andrew Callosofficer: EVP, Chief Commercial Officer | Sale | 15,000 | $85.80 | 58,555 |
| Jul 1, 2026 | Robert I. Blumdirector, officer: President & CEO | Sale | 7,500 | $84.92 | 377,830 |
CongressHouse and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Gilbert Cisneros · CA31 | Purchase | $1,001 – $15,000 | Jun 30, 2026 | Jul 3, 2026 ↗ |